Product
Cabazitaxel
Aliases
cabazitaxel, Jevtana, RPR-116258A, Taxoid XRP6258 (1 other aliases)
Name
Jevtana
FDA Approved
Yes
23 clinical trials
1 organization
1 drug
54 indications
1 document
Indication
Prostate CancerIndication
Castration-ResistantIndication
Castration-Resistant Prostate CarcinomaIndication
Prostate Cancer, Stage IV AJCC v7Indication
Bladder CancerIndication
Prostate AdenocarcinomaIndication
BCR-ABL1-positiveIndication
Breast Cancer, Stage IVIndication
AnaemiaIndication
Hodgkin lymphomaIndication
Non-Hodgkin LymphomaIndication
Hodgkin Lymphoma, Ann Arbor Stage IVIndication
Stage IV Non-Hodgkin LymphomaIndication
Atypical chronic myeloid leukemiaIndication
BCR-ABL1 NegativeIndication
Blast Phase Chronic Myelogenous LeukemiaIndication
Chronic Myelogenous LeukemiaIndication
Pancreatic CancerIndication
Breast CancerIndication
Metastatic Malignant Solid NeoplasmIndication
UnclassifiableIndication
Primary MyelofibrosisIndication
Acute Lymphoblastic LeukemiaIndication
Recurrent Acute Myeloid LeukemiaIndication
Chronic Lymphocytic LeukemiaIndication
Recurrent Hematologic MalignancyIndication
Hodgkin LymphomaIndication
Myelodysplastic SyndromeIndication
Myeloproliferative NeoplasmIndication
Multiple MyelomaIndication
Small Lymphocytic LymphomaIndication
Acute Myeloid LeukemiaIndication
Refractory Chronic Lymphocytic LeukemiaIndication
Chronic Myelomonocytic LeukemiaIndication
Refractory Hematologic MalignancyIndication
Hodgkin's LymphomaIndication
Malignant Solid NeoplasmIndication
Refractory Non-Hodgkin LymphomaIndication
MyelofibrosisIndication
Stage III Pancreatic CancerIndication
Pancreatic AdenocarcinomaIndication
Castration Levels of TestosteroneIndication
prostate-specific antigen progressionIndication
Prostate cancerIndication
Small Cell Prostate CarcinomaDrug
CabazitaxelClinical trial
A Phase 2 Trial of Nivolumab Plus Ipilimumab, Ipilimumab Alone, or Cabazitaxel in Men With Metastatic Castration-Resistant Prostate CancerStatus: Active (not recruiting), Estimated PCD: 2022-04-05
Clinical trial
MK-5684-01A Substudy: A Phase 1/2 Umbrella Substudy of MK-5684-U01 Master Protocol to Evaluate the Safety and Efficacy of MK-5684-based Treatment Combinations or MK-5684 Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC)Status: Not yet recruiting, Estimated PCD: 2028-03-31
Clinical trial
A Phase 1b Study of JNJ-78278343, a T-cell Redirecting Agent Targeting Human Kallikrein 2 (KLK2), in Combination With Either JNJ-63723283 (Cetrelimab), Taxane Chemotherapy, or Androgen Receptor Pathway Inhibitors for Metastatic Castration-Resistant Prostate CancerStatus: Recruiting, Estimated PCD: 2025-06-30
Clinical trial
A Phase II, Open-label, Study to Assess the Efficacy, Safety, and Tolerability of AZD4635 in Combination With Durvalumab and in Combination With Cabazitaxel and Durvalumab in Patients Who Have Progressive Metastatic Castrate-Resistant Prostate Cancer (AARDVARC)Status: Completed, Estimated PCD: 2021-11-01
Clinical trial
A Phase II Study of Carboplatin, Cabazitaxel and Abiraterone in High Volume Metastatic Castration Sensitive Prostate CancerStatus: Active (not recruiting), Estimated PCD: 2023-06-19
Clinical trial
A Phase I/II Trial of Concurrent Chemohormonal Therapy Using Enzalutamide (MDV-3100) and Cabazitaxel in Patients With Metastatic Castration Resistant Prostate CancerStatus: Active (not recruiting), Estimated PCD: 2019-10-16
Clinical trial
A Phase 2 Clinical Trial of Pembrolizumab in Combination With Carboplatin and Cabazitaxel in Aggressive Variant Metastatic Castration Resistant Prostate CancerStatus: Recruiting, Estimated PCD: 2026-11-01
Clinical trial
Randomized Phase II Study of Docetaxel Versus Cabazitaxel Post Abiraterone or Enzalutamide ProgressionStatus: Active (not recruiting), Estimated PCD: 2024-07-30
Clinical trial
Cabazitaxel in Combination With 177Lu-PSMA-617 in Metastatic Castration-resistant Prostate CancerStatus: Recruiting, Estimated PCD: 2026-06-20
Clinical trial
Phase I/II Study of PEGylated Arginine Deiminase (ADI-PEG20) With Carboplatin and Cabazitaxel in Men With Aggressive Variant Prostate Cancers (AVPC)Status: Recruiting, Estimated PCD: 2025-12-31
Clinical trial
A Phase II, Single Arm Study of Chemoimmunotherapy for the Treatment of Men With Neuroendocrine or Aggressive Variant Metastatic Prostate Cancer (CHAMP)Status: Recruiting, Estimated PCD: 2024-12-01
Clinical trial
A Phase I/II Trial for the Use of Intravesical Cabazitaxel, Gemcitabine, and Cisplatin (CGC) in the Treatment of BCG-Refractory Non-muscle Invasive Urothelial Carcinoma of the Bladder CancerStatus: Active (not recruiting), Estimated PCD: 2026-04-01
Clinical trial
A Randomized Phase III, Factorial Design, of Cabazitaxel and Pelvic Radiotherapy in Patients With Localized Prostate Cancer and High-risk Features of RelapseStatus: Active (not recruiting), Estimated PCD: 2025-12-01
Clinical trial
Anti-Androgens and Cabazitaxel in Defining Complete Response in Prostatectomy (ACDC-RP Trial): A Randomized, Open-label, Multi-centre Phase-2 Study Evaluating the Pathological Complete Response (pCR) Rate Following Neoadjuvant Therapy in Participants With High-risk Prostate Carcinoma for Whom Radical Prostatectomy is IndicatedStatus: Completed, Estimated PCD: 2021-05-27
Clinical trial
Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) Trial: PRIMEStatus: Terminated, Estimated PCD: 2020-12-10
Clinical trial
An Exploratory Randomized Phase II Multicenter Trial of Abiraterone Acetate With or Without Cabazitaxel in Treatment of Metastatic Castration Resistant Prostate CancerStatus: Completed, Estimated PCD: 2023-10-13
Clinical trial
A Phase I Study of Neoadjuvant Chemotherapy Involving Cabazitaxel, Docetaxel, Mitoxantrone or Satraplatin (CDMS) Followed by Surgery for Patients With High Risk Localized Prostate CancerStatus: Recruiting, Estimated PCD: 2026-12-01
Clinical trial
Randomized Phase II Study of Olaparib Maintenance Following Cabazitaxel-Carboplatin Induction Chemotherapy in Men With Aggressive Variant Prostate Cancer (AVPC)Status: Active (not recruiting), Estimated PCD: 2024-06-30
Clinical trial
A Dynamic Allocation Modular Sequential Trial of Approved and Promising Therapies in Men With Metastatic Castrate Resistant Prostate CancerStatus: Active (not recruiting), Estimated PCD: 2026-03-31
Clinical trial
Phase I Trial of Weekly Cabazitaxel With Concurrent Intensity Modulated Radiation Therapy and Androgen Deprivation Therapy for the Treatment of Locally Advanced High Risk Adenocarcinoma of the ProstateStatus: Completed, Estimated PCD: 2015-07-21
Clinical trial
Cabazitaxel With Abiraterone Versus Abiraterone Alone Randomized Trial for Extensive Disease Following Docetaxel: The CHAARTED2 TrialStatus: Active (not recruiting), Estimated PCD: 2024-06-30
Clinical trial
Randomized Phase II Study of Platinum-Taxane-Cetrelimab Induction Followed by Niraparib Plus or Minus Cetrelimab Maintenance in Men With Aggressive Variant Prostate CancersStatus: Active (not recruiting), Estimated PCD: 2025-12-31
Clinical trial
A Phase III Study of Cabazitaxel With or Without Carboplatin in Patients With Metastatic Castrate-Resistant Prostate Cancer (mCRPC), Stratified by Aggressive Variant SignatureStatus: Not yet recruiting, Estimated PCD: 2027-06-30
Document
DailyMed Label: JevtanaOrganization
Sanofi-Aventis U.S. LLC